Fennec Pharmaceuticals (FENC) Common Equity (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Common Equity data on file, last reported at $35.5 million in Q4 2025.

• Quarterly Common Equity rose 704.09% year-over-year to $35.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.5 million (up 704.09% YoY) and the FY2025 annual result came in at $35.5 million, up 704.09% from the prior year.
• Common Equity rose to $35.5 million in Q4 2025, from -$4.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $35.5 million in Q4 2025 to a low of -$11.6 million in Q4 2023.
• A 5-year average of $3.6 million and a median of -$2.0 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity tumbled 475.84% — and 2025, when it surged 704.09%.
• Tracing FENC's Common Equity over 5 years: stood at $15.8 million in 2021, then tumbled by 116.29% to -$2.6 million in 2022, then sank by 352.39% to -$11.6 million in 2023, then jumped by 49.48% to -$5.9 million in 2024, then surged by 704.09% to $35.5 million in 2025.
• The last three Common Equity figures came in at $35.5 million (Q4 2025), -$4.5 million (Q3 2025), and -$7.5 million (Q2 2025), per Business Quant data.